Neuraly is focused on developing disease‑modifying agents for neurodegenerative disorders, primarily Parkinson’s and Alzheimer’s disease. Its lead program, NLY01, is a brain‑penetrant, long‑acting GLP‑1 receptor agonist that showed neuroprotective effects in preclinical models, including inhibition of microglial activation, prevention of neuronal death, slowed disease progression, improved motor and cognitive function, and extended lifespan in Parkinson’s models. NLY01 leverages a GLP‑1R class safety profile documented by approved diabetes treatments, and Neuraly expected to initiate a Phase 1 clinical trial in 2018. The company was formed in 2016 based on Johns Hopkins research and holds exclusive licenses to related patents; supporting data were published in Nature Medicine. Neuraly also reports two additional early‑stage pipeline candidates targeting complementary mechanisms. The company launched alongside a Series A financing to fund clinical development.

Total raised

$36M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2018